… had mild or moderate, laboratory-confirmed Covid… safety, efficacy, and virology data from
the phase 2, dose-finding component of a trial evaluating molnupiravir for the treatment of Covid…

… study of 1,074,856 outpatients with COVID-19 in Hong Kong showed that molnupiravir use
was … A retrospective cohort study of 920 patients with mild-to-moderate COVID-19 who were …

… As new trials have been published, the efficacy and safety of molnupiravir need … the efficacy
and safety of molnupiravir for the treatment of non-severe (mild or moderate) COVID-19, and …

… COVID-19, and we compared the effectiveness and safety of MOV with those of NMV/r. MOV
was prescribed four times more frequently than NMV/r, but the risk of disease progression …

… efficacy and safety of molnupiravir in nonhospitalized adults with mild to moderate COVID-…
potential benefits of molnupiravir for the treatment of mild to moderate COVID-19 based on …

… safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate
COVID… included patients with mild-to-moderate COVID-19 (asymptomatic, mild, and …

… the safety and effectiveness of Nirmatrelvir/Ritonavir versus Molnupiravir in the treatment of
mild-to-moderate COVID-… in cancer patients with COVID-19, Molnupiravir could be safer than …

… trial in adults in the community with mild to moderate covid-19 who were not vaccinated …
covid-19, some safety concerns still need to be explored with real world data. Apart from mild or …

… molnupiravir has shown promising efficacy and safety in phase I/II/III clinical trials. Studies
have shown that molnupiravir … -hospitalized adults with mild-to-moderate COVID-19 disease …

… effects of molnupiravir in treating COVID-19 remain uncertain. This systematic review aimed
to evaluate the efficacy and safety of molnupiravir for adult patients with mild or moderate …